Trade names "Solcoseryl" and "Actovegin" refer to the drug - deproteinized hemodialysis, which includes many low molecular weight components of blood serum and cell mass of dairy calves. "Solcoseryl" in ampoules in the form of gels or ointments increases the penetration of nutrients into the cell, as well as the use of oxygen (improves the delivery of glucose and oxygen to cells that are in a state of oxygen starvation - hypoxia), accelerates and stimulates the metabolism and regeneration of damaged tissues . At the same time, the synthesis of intracellular ATP increases, which contributes to the activation of reparative and regenerative processes in the tissues, stimulates the proliferation of body tissues due to cell multiplication (the proliferation mechanism works) of the connective tissue and the synthesis of collagen of the vascular walls. "Solcoseryl" in ampoules does not have a toxic effect.
Since 1996, this drug has been produced (developed by the world famous Swiss company Nycomed Holdings A / S). The properties of this drug have been studied only partially by pharmacological and chemical methods. It is used in different countries (widely in our country), but this substance is not approved for use as a medicine in Western Europe, Japan, Australia and other countries of the world. "Solcoseryl" goes on sale in ampoules of dark glass with a capacity of 2 and 5 ml. In 1 ml of solution for intramuscular or intravenous administration contains 42.5 mg (in terms of dry matter) of deproteinized dialysate. Ampoules are packed in cellular planimetric cardboard packs. Also, the drug is produced in the form of a gel or ointment, the release form is in tubes with a drug mass of 20 g.
A solution of the drug is administered intravenously or intramuscularly. For intravenous use, Solcoseryl is dissolved in ampoules in an aqueous solution of sodium chloride with a mass fraction of 0.9%, or in an aqueous solution of dextrose with a concentration of 5%, or in a mixture of these solutions with a ratio of 1: 1. To avoid inflammation of the veins, the introduction of the drug should be very slow. Intramuscularly apply a solution for injection (not more than 5 ml), put local injections. “Solcoseryl” is prescribed for diseases of the lower extremities due to impaired vascular patency or chronic venous insufficiency, trophic ulcers, diabetic angiopathy, 2nd and 3rd degree burns, pressure sores, destruction or softening of tissues as a result of prolonged exposure to fluids, and damage to the cornea of the eye. The use of the drug is indicated for radiation injuries and skin grafts.
At the same time, if necessary, the doctor may prescribe antibiotics, vasodilators. With special care, “Solcoseryl” is prescribed with the simultaneous use of drugs that increase blood potassium (potassium-sparing diuretics, potassium preparations, ACE inhibitors). Also, the pharmaceutical interaction of the Solcoseryl drug in ampoules simultaneously with phytoextracts is not recommended. The drug is incompatible with naftidrofuril, the parenteral forms of Ginkgo biloba and bicyclan fumarate. "Solcoseryl" is contraindicated in childhood and adolescence (up to 18 years). If adverse reactions are observed, then the use of this drug is suspended or discontinued. Careful use of Solcoseryl is also required (required under medical supervision and only in critical cases) during pregnancy. In periods when a woman is breastfeeding, the use of Solcoseryl is not allowed.
The use of the drug "Solcoseryl" (injections, gels and ointments) is allowed only as directed by a doctor. The instructions that are in the package with the drug, as well as this article are for informational purposes and cannot replace the prescription of the doctor who will prescribe the method of use, dosage, and also evaluate the possibility of simultaneous treatment with other drugs.